Comparison finds Ga-FAPI PET/CT outperforms FDG PET/CT in evaluating nasopharyngeal carcinoma, suggesting clinical benefits.
Gallium 68 fibroblast activation protein inhibitor PET/CT outperformed conventional methods (plasma Epstein-Barr virus DNA level, contrast-enhanced MRI/CT, and fluorine 18 fluorodeoxyglucose PET/CT) in nasopharyngeal carcinoma primary evaluation and recurrence monitoring, suggesting its potential clinical utility.
No takes yet. Share an insight, caveat, or question.
Gu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: